MannKind (MNKD) Stock Continues to Decline Wednesday

NEW YORK (TheStreet) -- MannKind  (MNKD) continued to decline Wednesday after news on Monday that the FDA had approved the biopharmaceutical company's inhaled insulin drug Afrezza.

The stock surged by double digits on Monday but declined Tuesday after MLV & Co. downgraded the stock to "hold" from "buy." The firm is curbing its expectations for Afrezza until the next step in the process.

"Our next immediate focus is the commercial partnership for Afrezza," the firm wrote in a research note. "Which pharma MNKD secures as a partner and partnership deal terms will be major factors in determining how the market (and stock) reacts. We expect partnership news in the next two to three months (but are hopeful it could come sooner), and note that we'll likely use that event as an opportunity to re-evaluate our views on the stock and Afrezza's prospects."

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was down 4.48% to $9.86 at 12:11 p.m.

MNKD Price Chart

MNKD Price data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Mannkind in Free Fall After Changes to Insulin Product, Sales Force

Mannkind Stock Drops Following Changes to Its Insulin Product

Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open

Insulin Drug Offers Hope for MannKind